Metabolic Peptides — Incretin Agonism, Fat Metabolism, and Exercise Mimetics

Three Approaches to Metabolic Research

The OSYRIS Metabolic category is the largest in the catalog with 6 primary compounds (plus cross-listings). These compounds fall into three distinct pharmacological approaches:

Approach 1: Incretin Receptor Agonism

The incretin progression is OSYRIS's most distinctive offering. No other vendor provides all three agonism levels (single, dual, triple) plus amylin agonism in research-grade format. This enables systematic subtractive pharmacology: testing each level under identical conditions to isolate the contribution of each additional receptor.

The key insight: Each receptor adds qualitatively different metabolic effects, not just more of the same:

• GLP-1 alone: appetite suppression + insulin secretion + gastric slowing
• + GIP: adipose tissue insulin sensitization + potential bone protection + anti-nausea
• + Glucagon: hepatic fat oxidation + thermogenesis + energy expenditure increase

Cagrilinitide represents a fourth pathway (amylin) that modulates appetite through brainstem circuits distinct from GLP-1's hypothalamic mechanisms. It's studied both alone and in combination with GLP-1 agonists.

Approach 2: Direct Fat Metabolism

AOD-9604 takes a completely different approach to metabolic research. Rather than modulating appetite through receptor signaling, it directly stimulates fat breakdown (lipolysis) and inhibits fat formation (lipogenesis) in adipose tissue. It's the C-terminal fragment of growth hormone — the specific piece responsible for GH's fat-metabolizing effects, isolated from all other GH activities.

What makes this approach distinct: AOD-9604 doesn't affect appetite, insulin, glucose, or IGF-1. It's a direct intervention on fat tissue metabolism through beta-3 adrenergic receptors. This makes it a clean tool for studying fat metabolism independent of appetite and glucose variables.

Approach 3: Exercise-Mimetic Metabolism

SLU-PP-32 and MOTS-C (cross-listed from Longevity) represent pharmacological tools for studying exercise-induced metabolic adaptation without physical activity:

• SLU-PP-32 activates ERR (estrogen-related receptors) — nuclear receptors that drive exercise-induced gene expression programs including mitochondrial biogenesis and fatty acid oxidation.
• MOTS-C activates AMPK — the cell's energy sensor that triggers the metabolic cascade normally activated by exercise.

Different targets (ERR vs AMPK), same research question: which exercise benefits are mediated by each specific pathway?

The Complete Metabolic Research Toolkit

Evidence Strength by Compound

The Metabolic category has the widest range of evidence quality in the OSYRIS catalog:

Strongest evidence: GLP-1 (S), GLP-2 (T) — backed by extensive Phase 3 clinical trials with thousands of participants. These have the most robust human data of any compounds OSYRIS sells.

Moderate evidence: GLP-3 (R) — Phase 2 clinical data (smaller sample sizes, shorter duration). AOD-9604 — Phase 2 trial data (safety confirmed, efficacy equivocal). Cagrilinitide — Phase 2 data in combination studies.

Early evidence: SLU-PP-32 — preclinical with limited published data. MOTS-C — growing preclinical data from one primary laboratory.

Researchers should calibrate their expectations to the evidence level of each compound.